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CLINICAL INVESTIGATION
Anti-a-galactosyl antibodies and immune complexes in children
with Henoch—Schönlein purpura or IgA nephropathy
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Anti-a-galactosyl antibodies and immune complexes in children with
Henoch—Schönlein purpura or IgA nephropathy. Episodes of hematuria
in IgA nephropathy or Henoch—SchOnlein purpura are frequently asso-
ciated with microbial infections. Some of those infectious agents bear
a-galactosyl residues on their cell surface. These observations
prompted us to determine, by passive hemagglutination, the titers of
natural anti-galactosyl antibodies in the serum of children presenting
with Henoch—Schonlein purpura (10 cases) or IgA nephropathy (7
cases). Antibody titers of normal subjects (103 cases), children with a
pharyngitis of unknown etiology (7 cases), and children exhibiting
mesangial IgA deposits but no hematuria at the time of testing (6 cases)
ranged from 1:20 to 1:80. Elevated titers (> 1:80) were observed in nine
of 11 patients with mesangial IgA deposits and micro- or macroscopic
hematuria, in nine of 19 children with other evolutive glomerular
diseases (5 cases of acute glomerulonephritis and 4 cases of minimal
change disease), and in most subjects presenting with a M. pneumoniae
(4/5 cases) or a E. Coli (4/5 cases) infection. Antibody titers decreased
after incubation of normal and pathological sera with D-galactose (10
mM) or with a-galactosyl—glucoside (10mM), but not with D-glucose (10
mM). The anti-a-galactosyl antibodies purified, by affinity chromatog-
raphy, from sera of 10 normal children, 10 pathological controls and
four children with mesangial IgA deposits without hematuria belonged
to IgG class. In contrast, both IgG and IgA anti-a-galactosyl antibodies
were detected in six of six patients with mesangial IgA deposits and
hematuria. The IgA content of immune complexes detected in those
patients decreased after incubation of sera with a-galactosyl—glucoside,
but not with D-glucose. We conclude that an IgA anti-a-galactosyl
immune response is frequently observed during hematuria episodes in
IgA-associated nephrites.
Numerous clinical and histopathological observations sug-
gest that the pathogenesis of IgA nephropathy and Henoch—
Schönlein purpura nephritis is related to the deposition of IgA
and/or of IgA-containing immune complexes in the glomerular
mesangium. Indeed, mesangial IgA deposits [1, 21, high IgA
plasma levels [2—41 and circulating IgA-containing immune
complexes [5—8] have been observed in both nephropathies.
Furthermore, the in vitro production of IgA by lymphocytes of
these patients is markedly increased as compared to normal
subjects [9], and the impairment of the reticuloendothelial
system phagocytic function observed in those nephropathies
[10, 11] may facilitate the mesangial deposition of IgA-contain-
ing immune complexes. Support for the role of IgA and/or of
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IgA-containing immune complexes in the development of
glomerular lesions is derived from experimental models of
IgA-glomerulonephritis (GN) induced either by oral immuniza-
tion of mice with various exogenous proteins [12] or by intra-
venous injection of preformed IgA immune complexes [13].
As in other forms of human GN, the antigen(s) involved in
IgA nephropathy or Henoch—SchOnlein nephritis remain(s) un-
known. Macroscopic hematuria episodes are frequently accom-
panied by upper respiratory tract infections in IgA nephropathy
[4], whereas gastrointestinal symptoms are frequently observed
during Henoch—SchOnlein syndrome [2]. IgA nephropathy has
been reported to occur in association with urinary tract infec-
tions by E. Coli [14]. Antibodies directed against Mycoplasma
EM.] pneumoniae and certain E. Coli serotypes have also been
reported during acute macroscopic hematuria episodes occur-
ring in those renal diseases [14]. M. pneumoniae can cause
upper, as well as lower, respiratory tract infections [15]. E. Coli
is present in the intestinal flora. The immunodominant antigenic
site of M. pneumoniae is located in a glycosphingolipid contain-
ing a-galactosyl residues [161. Some E. Coli serotypes bear
a-galactosyl groups on their cell wall [17]. Recently, Galili et a!
[18] have shown the presence of natural IgG, but not IgA,
anti-a-galactosyl antibodies in the serum from normal subjects
of all blood groups. As for anti-blood group antibodies, they
have suggested [18] that the production of anti-a-galactosyl
antibody throughout life implies a permanent antigenic stimu-
lation which may originate from the intestinal flora. The major-
ity of IgA producing lymphoid tissue is associated with the
mucosal surface [19, 20]. These considerations prompted us to
test the possibility that in IgA nephropathy and Henoch—Schön-
1cm nephritis, acute phases of the disease are associated with
the occurrence of IgA anti-a-galactosyl antibody into the circu-
lation. We have also examined the possibility that some IgA
immune complexes detected in patients presenting with IgA
nephropathy or Henoch—SchOnlein nephritis might contain IgA
anti-galactosyl antibodies.
Methods
Patients and controls
Nine boys and eight girls aged from four to 17 years,
presenting with either a Henoch—Schönlein purpura nephritis
(10 cases) or an IgA nephropathy (7 cases) were selected for the
present study. Their main clinical features are summarized in
Table 1. Patients were divided in two groups according to the
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Table 1. Some clinical and biological features of patients presenting with mesangial IgA deposits
Patient
number
Age
years Sex Diagnosisa Hematuria"
Anti-galactosyl
antibody titers
IgA immune
complexes
levels ng/ml°
1 8 M IgA N + (M) 1/160 1560
2 5 F IgA N + (m) 1/160 1480
3 17 M IgA N + (m) 1/160 2680
4
5
6
15
5-7!2
F
F
M
M
HSP
HSP
HSP
HSP
+
+
+
+
(m)
(m)
(m)
(M)
1/160
1/160
1/160
1/160
1680
1740
420
1820
8 7- F HSP + (m) 1/160 2800
9
10
12-i
14 2
F
M
HSP
HSP
+
+
(m)
(m)
1/320
1/80
1860
400
11
12
13
17
4-
72
F
F
M
HSP
HSP
HSP
+
—
—
(M) 1/40
1/80
1/40
1100
340
0
14
15
16
17
98-
12 2
12-i
F
M
M
M
IgA N
IgAN
IgA N
IgA N
—
—
—
—
1/40
1/80
1/40
1/80
280
1140
1540
370
Abbreviations are: IgA N, IgA nephropathy; HSP, Henoch—SchOnlein purpura
b M, macroscopic hematuria; m, microscopic hematuria (more than 5 red blood cells per cubic millimeter)
IgA immune complexes levels in normal sera were lower than 560 ng/ml (Fig. 3)
existence (11 cases) or not (6 cases) of hematuria at the time of
testing. The hematuria was macroscopic in three cases and
microscopic (more than 5 red blood cells per cubic millimeter)
in eight cases. Six of these latter patients had presented bouts of
macroscopic hematuria five to 12 days prior to the study. Bouts
of macroscopic hematuria were associated with upper respira-
tory tract infections in five out of eight patients. Plasma
creatinine level was 18 mg/liter in patient no. 11, 10 mg/liter in
patient no. 13 and normal in the other patients. The liver
function was normal in all cases and none were taking steroids
at the time of testing. Anti-DNA antibodies were not detected in
any patient. Normal controls consisted of 62 adults and 41
children aged from two to 14 years. In addition, 19 children
aged from five to 13 years and suffering from other evolutive
glomerular diseases were studied. They exhibited either an
acute post-streptococcal GN (12 cases) or a minimal change
glomerular disease (MCGD) (7 cases). They presented with
either a macroscopic hematuria (5 cases), a microscopic
hematuria (7 cases) or a nephrotic syndrome (7cases). Patients
suffering from active mucosal infections not associated with
renal involvement were also examined. These were five adults
with interstitial pulmonary disease secondary to M. pneumo-
niae, five children (age: 3 to 10 years) with a E. Coli gastroin-
testinal infection, and seven children (age 6 to 14 years) with
a pharyngitis of unknown etiology. Diagnoses of M. Pneumo-
niae and of E. Coli infections were made by classical serological
and/or bacteriological analyses. All blood samples were col-
lected from fasting subjects and allowed to clot at 4°C. Sera
were stored at —20°C until used.
Measurement of circulating anti-a-galactosyl antibody titers
Rabbit red blood cells (RBC), bearing a-galactosyl residues
on their surface membrane [181, were used in an agglutination
assay for anti-cs-galactosyl antibodies. Two ml of rabbit hepa-
rinized blood were centrifugated at 2,000 rpm for 15 minutes.
The pellet was washed three times in phosphate—buffered
saline, pH 7.4 (PBS). A 1% RBC suspension was obtained by
dilution of this pellet in PBS. Complement was inactivated by
heating the sera at 56°C for 30 minutes. Hemagglutinating
activity was titrated by mixing twofold serial dilutions of sera in
PBS with an equal volume of 1% rabbit RBC suspension in 5 ml
plastic tubes. Agglutination was evaluated after two hours.
Titers were expressed as the highest dilution that caused
complete agglutination of rabbit RBC.
In order to evaluate whether the presence of whole serum
IgG influenced the hemagglutination reaction [18], titers of
affinity—purified anti-galactosyl antibodies (described below)
were measured after addition of 100 g of antibody to 1 ml of
either PBS, IgG-depleted normal human serum (Nordic Labo-
ratories, Tilburg, The Netherlands), or normal human serum
pre-absorbed with rabbit RBC. Comparable titers were ob-
tained in those three experimental conditions (1/40). The a-
galactosyl specificity of antibodies detected in 20 normal and 20
pathological sera was studied by immunoabsorption experi-
ments performed according to the method of Galili et al [18].
Briefly, one volume of serum was mixed for two hours at 37°C
with one volume of 10 m iso-osmotic NaCl solutions of either
a-galactosyl—glucoside (melibiose), D-galactose, or D-glucose.
These relatively high concentrations were chosen to theoreti-
cally achieve a strong inhibition of passive hemagglutination
reaction [18]. At the end of incubation, hemagglutinating titers
were determined as described above.
Purification of circulating anti-a-galactosyl antibodies
Purification of anti-a-galactosyl antibodies was as described
[18]. Briefly, anti-galactosyl antibodies from heat—inactivated
sera (100 ml) of normal individuals of AB, Rh+, blood group
were affinity—purified on a melibiose—Agarose column of 10 ml
(Sigma Chemical Co., St. Louis, Missouri, USA). Bound anti-
bodies were eluted from the affinity column with 20 ml of a 0.5
M D-galactose solution. The IgG was then purified from the
elutate by passage through a 5 ml column of protein A-
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Sepharose (Sigma). The IgG eluted in 10 ml of glycine—HC1
buffer, pH 2.6, was immediately neutralized with 10 ml of
Tris-HCI buffer, pH 8.4. After extensive dialysis against PBS,
purified IgG was absorbed with Vibrio-cholera neuraminidase
(Sigma)-treated human RBC, to remove any eventual anti-
Thomsen Friedenreich antibody activity [18, 21]. After centrif-
ugation at 2,000 rpm for five minutes, the IgG content of
supernatants was assessed by quantitative radial immunodiffu-
sion [22]. About 3 mg of IgG were recovered from 100 ml of
sera.
Anti-galactosyl antibodies were also purified from 2 to 5 ml of
serum from the following subjects: (a) ten normal controls of all
blood groups; (b) ten patients presenting with either an IgA
nephropathy (cases no. 1, 2, 3, 16, 17) or a Henoch—SchOnlein
nephritis (cases no. 6, 7, 8, 12, 13); (c) five patients presenting
with either an acute post-streptococcal GN (3 cases) or a
MCGD (2 cases); (d) five patients presenting with either a M.
pneumoniae (2 cases) or an E. Coli infection (3 cases). In these
experiments, samples were first incubated with melibiose—
agarose at 4°C in a tube on a rotator for 48 hours [23]. The beads
were then poured into small columns. After washing, bound
antibodies were eluted from the affinity—columns as described
above. After dialysis against 1 liter of PBS and absorption on
neuraminidase—treated human RBC, antibodies were passed
through small protein A-columns (0.5 ml), and bound material
was eluted with 1 ml of glycine-HC1 buffer, pH 2.6. After
extensive dialysis against distilled water, bound and unbound
material was lyophilized. The protein content of bound and
unbound material was then measured by the method of Lowry
et al [24], using human IgG as a standard.
The class of antibodies was determined either by im-
munoelectrophoresis [25] performed using monospecific goat
antisera directed against human IgG, IgA or 1gM (Nordic
Laboratories), or by indirect immunofluorescence. For im-
munofluorescence microscopy, a solution of 10 p.g of bound or
of unbound antibodies in 100 sl of PBS was mixed for one hour
at 37°C with 100 jd of a 1% rabbit RBC suspension in PBS.
After three washings with PBS, the last pellet resuspended in
100 d of PBS was incubated for one hour at 37°C with 100 d of
fluoresceinated goat anti-human IgG, IgA or 1gM antibodies
(Nordic Laboratories) diluted 10 times in PBS. After three
further washings with PBS, the red cells were examined under
a UV microscope. The apparent molecular weight of antibodies
was measured by polyacrylamide gel electrophoresis [26]. The
Ig concentrations in bound and unbound fractions of protein
A-columns were also determined by quantitative radial immu-
nodiffusion [22].
Polyethylene glycol (PEG) assay
PEG precipitation. One hundred d of sera were incubated
for one hour at 37°C with 100 d of a 5% PEG solution in borate
buffer, pH 8.3 (PEG 6,000, Fluka AG, Buchs, Switzerland). A
2.5% final concentration was chosen instead of 3.5% [27] in
order to precipitate IgA molecules of large or intermediate sizes
only. The 2.5% PEG pellet obtained after centrifugation at 2,400
rpm for 20 minutes was washed three times with 2.5 ml of a
2.5% PEG solution in borate buffer. The IgA content of the last
pellet resolubilized in PBS was then measured by a solid phase
radioimmunoas say.
Solid phase radioimmunoassay. IgA-coated wells were pre-
pared as follows: 100 d of a 2 mglml secretory IgA (Sigma)
solution diluted 10 times in PBS were allowed to stand in wells
of flexible polyvinylchloride plates (Becton and Dickinson,
Oxnard, California, USA) for two hours at 37°C. The coating
efficiency of secretory IgA, estimated by measuring by the
method of Lowry et al [24] the protein content of ten superna-
tants collected at the end of this incubation, was always higher
than 80%. Wells were then emptied and filled with 100 d of a
5% bovine serum albumin (BSA) solution in PBS for one hour
at room temperature. After three washings with PBS, the plates
were air dried and stored at 4°C until use. The standard curve
was established as follows: increasing amounts (from 100 ng to
30 gig) of secretory IgA were first mixed for one hour at 37°C in
5 ml plastic tubes with one ml of a 1.5 mglml solution of rabbit
anti-human a-chain antibody (Behringwerke AG, Marburg,
West Germany) diluted 10,000 times in PBS containing 0.05%
Tween 20 (PBS-Tween) and 1% BSA. These experimental
conditions were chosen on the basis of preliminary data show-
ing that, at that dilution, the binding of anti-a-chain antibodies
to IgA-coated plates reached 40 to 50% of maximal binding.
Fifty tl aliquots of standard solutions (containing 5 to 1,500 ng
of IgA) were then added to the IgA coated wells for one hour at
37°C. AFter three washings with PBS Tween, 50 d of 125J
labeled protein A (about 30,000 cpm; specific activity: 2 p,Ci/g)
(NEN, Boston, Massachusetts, USA) solution in PBS were
added to each well for one hour at 37°C. After three further
washings with PBS Tween, the radioactivity of each well was
determined in a gamma spectrometer (LKB-Wallac Rackgam-
ma 111270, Turku, Finland) with a counting efficiency of 63%.
Each point of the standard curve was tested in triplicate. The
lower limit of sensitivity of the assay was 50 ng/ml. Within run
and between day variation coefficients, calculated according to
classical formulas [28] were 5.3% and 8.7%, respectively. For
the measurement of the IgA content of 2.5% PEG precipitates,
the last pellet obtained by centrifugation at 2,400 rpm for 20
minutes was resolubilized in 100 d of PBS containing the rabbit
anti-human a-chain antibodies diluted 10,000 times. One hour
later, fifty al of this solution were added to the IgA coated
wells. The samples were then processed as for the standard
curve. Each sample was tested in duplicate. Results were
expressed in ng/ml.
The IgA content of 2,5% PEG precipitates was also measured
as described above after a prior incubation of sera for one hour
at 37°C with an equal volume of either 10 mrvi melibiose or 10
m glucose solutions. The effects of melibiose or of glucose
incubations on the IgA content of 2.5% PEG precipitates were
also evaluated as follows: 2.5% PEG pellets obtained from 100
l of sera were solutilized in 100 d of borate buffer and then
incubated for one hour at 37°C with 100 p1 of a 10 m solution
of either melibiose or glucose. An equal volume of 5% PEG was
then added to the latter mixture. After a further one hour
incubation at 37°C, the IgA content of the PEG pellet obtained
by centrifugation at 2,400 rpm for 20 minutes was determined as
already described.
Biological studies
IgG, IgA, 1gM, C3, C4 and C3PA plasma levels were deter-
mined with monospecific antisera by laser nephelometry
(Hyland Co., Travenol, Deerlield, Illinois, USA). The following
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from 1:40 to 1:320, and thus nine of 19 patients exhibited
elevated titers (Fig. 1C) (5 cases of acute GN and 4 cases of
MCGD). Elevated titers also occurred in eight of 10 patients
with mucosal infections by E. Coli or by M. pneumoniae (Fig.
1D). Children presenting with a pharyngitis of unknown etiol-
ogy (7 cases) exhibited normal titers (Fig. lD).
The anti-galactosyl antibody titers were then assessed in 20
normal and 20 pathological sera before and after incubation
with 10 m solutions of either melibiose, D-Galactose or
D-Glucose. Titers were always reduced by two to three serial
dilutions in the presence of melibiose or D-Galactose, whereas
no changes in the titers occurred after a prior incubation of sera
with D-Glucose (data not illustrated).
Characterization of anti-cr-galactosyl antibodies
Fig. 1. Anti-galactosyl antibody titers in 41 normal children () and 62
normal adults (D) (A), in 17 patients presenting with mesangial IgA
deposits (B), in 19 patients presenting with other glomerular diseases
(acute post-streptococcal GN or MCGD) (C), and in 17 patients
suffering from an active mucosal infection without renal involvement
(D): (•) pharyngitis of unknown origin; () infections by E. Coli or M.
Pneumoniae.
parameters were also measured using classical methods: sedi-
mentation rate, fibrinogen, haptoglobin and ceruloplasmin
plasma levels. Urinary analyses (proteinuria, hematuria) were
performed by routine techniques.
Results
Titers and specificity of anti-galactosyl antibodies
The titers of anti-galactosyl antibodies in 41 normal children
and in 62 normal adults ranged from 1:20 to 1:80 with a
frequency peak centered on the 1:40 dilution (Fig. 1A). Titers
higher than 1:80 were therefore arbitrarily considered as ele-
vated. In the group of patients presenting with either a
Henoch—Schonlein purpura or an IgA nephropathy, antibody
titers ranged from 1:40 to 1:320 and, according to the matched
control group of children, nine of 17 patients (53%) exhibited
elevated titers (>1:80) (Fig. lB). In the group of children
presenting with other glomerular diseases, titers also ranged
The concentration and the class of anti-a-galactosyl antibod-
ies purified by affinity chromatography from the sera of normal
subjects, patients and controls are summarized in Table 2. The
concentration of anti-a-galactosyl antibody was higher (93 to
165 ig/ml) in serum samples from patients presenting with
active glomerular diseases than in samples from normal chil-
dren (29 to 79 gIml) or from children presenting with mesangial
IgA deposits not associated with hematuria at the time of testing
(42 to 69 g/ml). The antibody concentrations during M. pneu-
moniae or E. Coli infections ranged from 90 to 124 g/m1 (Table
2). The antibodies belonged only to the IgG class in all normal
children and controls, whereas they belonged to both IgG and
IgA classes in six out of six children suffering from active
glomerular diseases associated with mesangial IgA deposits, as
demonstrated by quantitative radial immuno-diffusion (Table
2), by immunoelectrophoresis (Fig. 2B) and by indirect im-
munofluorescence (Fig. 2C). The apparent molecular weight of
antibodies, determined by polyacrylamide gel electrophoresis,
was about 160,000 (Fig. 2A). Prior incubation of affinity—puri-
fied antibody (100 g/ml) with 10 m solutions of melibiose
completely inhibited the hemagglutination of rabbit RBC,
whereas similar solutions of D-Glucose had no effect on the
hemagglutinating titers (data not illustrated).
Correlations between the anti-galactosyl antibody titers, IgA
immune complexes and the hematuria episodes
In 10 normal children, the 2.5% PEG precipitates of sera
contained less than 560 ng/ml of IgA and their mean IgA
concentration (± SEM) was 134 69.8 ng/ml (Fig. 3). In 11 of 17
patients, the 2.5% PEG precipitates contained more than 560
ng/ml of IgA (Fig. 3, Table 1). Furthermore, the mean IgA
concentration in the 2.5% PEG precipitates of pathological sera
was significantly higher than that of controls (P < 0.01) (Fig. 3).
Considering in the 17 patients presenting with mesangial IgA
deposits those that exhibited an active renal disease, that is,
hematuria at the time of testing (11 cases), nine had elevated
anti-galactosyl antibody titers (> 1/80, Table 1). Considering in
the same patients those that exhibited no hematuria (6 cases),
none presented with elevated antibody titers (Table 1). Simi-
larly, IgA immune complexes were more frequently detected in
patients presenting with hematuria (9 of 11 cases) than in
patients presenting no hematuria (2 of 6 cases) when they were
tested (Table 1). Although no significant linear correlation could
be established between the IgA content of 2.5% PEG precipi-
A
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Table 2. Concentration and class of affinity—purified anti-a-galactosyl
antibodies in normal children, patients with mesangial IgA deposits
and control subjects
Normal
children
number
Protein
concentrationa
g/ml
Class of antibodies"
IgG IgA 1gM
1 32 +(28) — —
2 29 + — —
4 30 +(29) — —
6 35 +(32) — —
8 58 + — —
9 52 + — —
11 61 +(64) — —
14 49 + — —
16 76 +(69) — —
18 79 +(74) — —
Patient number
1 115 + (80) + (31) —
2 132 + (96) + (28) —
3 144 + + -
6 112 + (82) + (23) —
7 153 + (102) + (38) —
8 165 + + —
12 42 + — —
13 61 +(58) — —
16 34 + — —
17 69 +(60) — —
Control subject
number'
1 120 +(llO) — —
2 102 +(109) — —
3 90 + — —
4 112 + — —
5 124 + — —
6 121 +(112) — —
7 96 + — —
8 132 +(116) — —
9 115 +(108) — —
10 93 +(90) — —
a Determined by the method of Lowry et al [24], using normal human
IgG as a standard
b Assessed by immunoelectrophoresis or by indirect immuno-
fluorescence; the number in brackets represents the Ig concentration
(jgIml) measured by quantitative radial immunodiffusion [221
Controls included 2 subjects with a M. pneumoniae infection (cases
I and 2), 3 with a E. coli infection (cases 3 to 5), 3 with an acute
post-streptococcal GN (cases 6 to 8) and 2 with a MCGD (cases 9 and
10)
tates and the anti-galactosyl antibody titers, elevated titers were
more frequently encountered in patients presenting with IgA
immune complexes (8 of 11 cases) than in those exhibiting no
IgA immune complexes (1 of 6 cases, Table 1).
Elevated plasma levels of IgA were noted in 10 out of 17
cases of IgA-associated nephrites, five of those 10 patients
exhibiting hematuria when they were tested. However, among
the nine patients presenting with elevated anti-galactosyl anti-
body titers, four exhibited normal and five elevated IgA plasma
levels (data not illustrated). Furthermore, patients with ele-
vated titers did not differ from the others by some other
immunological characteristics, that is, IgG, 1gM, C3, C4 and
C3PA plasma levels, or by some biological characteristics, such
as sedimentation rate or fibrinogen, haptoglobin and cerulo-
plasmin plasma levels.
Effects of melibiose or glucose on the IgA content of 2.5%
PEG precipitates
The IgA content of 2.5% PEG precipitates was measured by
radioimmunoassay in four control children and in eight patients
before and after melibiose or glucose treatment either of whole
serum or of 2.5% PEG precipitates. Similar results were ob-
tained with both types of samples. It was found (Fig. 4) that the
IgA content of the 2.5% PEG precipitates remained unchanged
after incubation with melibiose (or glucose) solution in the four
control subjects, On the contrary, the IgA content of 2.5% PEG
precipitates significantly decreased after incubation with meli-
biose—but not with glucose—in the eight patients studied.
Discussion
In the present work, rabbit RBC were used in an agglutina-
tion assay for the detection of anti-a-galactosyl antibodies,
since these erythrocytes bear a-galactosyl residues on their
surface membrane [18]. A rosette assay using either K562 cells
[18] or human monocytes [29] was not performed for the
following reasons: (a) passive hemagglutination is an easy and
reproducible method measuring the overall reactivity of RBC;
(b) rosette assays only involve a small fraction of the total RBC
population [30], rosette formation depends on RBC to target
cell ratios, and accurate readings are rather cumbersome when
those ratios are high (100:1) [23]. The first finding that emerged
from our studies is that the micro- or macroscopic hematuria
episodes occurring in Henoch—Schönlein nephritis and in IgA
nephropathy are associated with elevated anti-galactosyl anti-
body titers. This conclusion is supported by the following
observations: (a) in 41 normal children and 62 normal adults,
antibody titers ranged from 1:20 to 1:80; (b) elevated titers (>
1:80) were noted in 80% of patients presenting with hematuria,
whereas the antibody titers remained within the normal range in
all patients presenting with no hematuria at the time of testing;
(c) the antibody titers were always reduced in the presence of
melibiose or D-galactose, but not of D-glucose. However,
elevated anti-galactosyl antibody titers were not observed in
those nephropathies only. They were also noted in about 50% of
control patients exhibiting either an acute post-streptococcal
glomerulonephritis or a minimal change glomerular disease.
The trihexose ceramide, Gal a (1 —* 4) Gal /3 (1 — 4) Glc-o-
ceramide, is one of the lipids present in membranes of human
kidney cells [31]. A kidney lesion may therefore enhance the
anti-a-galactosyl response by a release of some galactos-
yl—containing antigens into the bloodstream, as has been sug-
gested [32].
Antibodies to blood group B can be increased in man by the
oral administration of E. Coli 086 [33]. As for anti-blood group
antibodies, anti-galactosyl antibodies are probably produced
throughout life by a permanent antigenic stimulation which may
originate from the intestinal flora. This is in agreement with the
fact that elevated anti-galactosyl antibody titers were also found
in most control subjects with a E. Coli or a M. pneumoniae
infection. Some of those infectious agents indeed bear a-
galactosyl residues on their cell surface [16, 17], and they are
usually potent B cell activators [34, 35].
We have noted that no complete inhibition of the hemagglu-
tination reaction was achieved even in the presence of relatively
high concentrations (10 mM) of either melibiose or D-galactose.
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Fig. 2. A. Polyacrylamide gel electrophoresis in dodecylsulfate ofanri-a-galactosyl antibodies purified by affinity chromatography from the serum
of a patient presenting with a Henoch—SchOnlein purpura (case no. 6; Table 1). The apparent mol wt of antibodies was calculated by comparison
with the relative mobility of IgG standard. The arrows denote the dye front. B. Immunoelectrophoresis of anti-a-galactosyl antibodies purified from
the serum of the same patient. In presence of anti-human IgG antiserum one single precipitin line is observed with material bound to and
subsequently eluted from the protein A column (a), whereas no precipitin line is noted with unbound material (b). On the contrary, in presence
of anti-human IgA antiserum, no precipitin line is observed with bound proteins (c), whereas a precipitin line is obvious with unbound fraction (d).
Ten g of protein have been loaded into each well. The anode is on the left. C. Immunofluorescence microscopy of rabbit erythrocytes successively
incubated with 10 g of affinity purified anti-a-galactosyl antibodies unbound to protein A, and with fluoresceinated goat anti-human IgA antibody
diluted 10 times in PBS. Antibodies were isolated from the serum of patient no. I (Table 1). Erythrocytes forming a small agglutinate are strongly
stained (original magnification x 400).
This result strongly suggests that antibodies other than anti-a-
galactosyl antibodies were also responsible for hemagglutina-
tion of rabbit RBC. The other specificities may include
anti-Thomsen Friedenreich antibodies [36], blood group B
substances [37], human erythrocyte P1 and pk blood group
glycolipids [38], anti-I-antibodies [38] and serum sickness anti-
bodies [39]. In order to avoid those reactivities, all subsequent
experiments were conducted using affinity—purified anti-a-
galactosyl antibodies. The main specific finding observed in
nephropathies with mesangial IgA deposits is that the immune
response towards a-galactosyl—containing antigens involves
antibodies not only of the IgG class, but also of the IgA class.
Indeed, we have shown by immunoelectrophoresis, by im-
munoabsoi-ption experiments on protein A columns, by indirect
immunofluorescence and by quantitative radial immunodiffu-
sion, that affinity—purified anti-a-galactosyl antibodies belonged
to both IgG and IgA classes during the micro- or macroscopic
hematuria episodes occurring in IgA-associated nephrites,
whereas they belonged to the IgG class only in all the normal
and pathological controls tested. The reason(s) why circulating
anti-a-galactosyl IgA antibodies are only detectable during
acute phases of Henoch—SchOnlein purpura or of IgA nephritis
remain(s) unknown. In addition, to assess the pathogenetic
significance of such an association, prospective studies will be
needed, as well as the demonstration of anti-galactosyl antibod-
ies in renal biopsies.
Several techniques have been used to detect circulating
IgA-containing immune complexes in man. Their principles rest
either upon the high affinity binding of certain components of
the complexes to specific receptors [40, 41] or upon the precip-
itation of complexes by PEG solutions [27, 42]. Our method is
based on the second principle. It is well known from numerous
experimental models that the mesangial matrIx mainly entraps
large immune complexes. In addition, the apparent molecular
weight of a significant proportion of IgA molecules eluted from
renal biopsies of patients with IgA nephropathy is higher than
1,000,000 daltons [43]. The mechanisms of action of PEG
remain poorly understood, but could be similar to that of
dextran, that is, a steric exclusion of antigen—antibody com-
plexes from the domain of the polymer [44]. The size of the
immune complexes excluded is inversely related to the PEG
concentration. We have thus chosen a very low PEG concen-
tration to mainly precipitate large IgA immune complexes.
Preliminary results obtained with patients exhibiting IgA-
associated nephrites are of interest. Indeed, we have noted that
the IgA content of 2.5% PEG precipitates of sera from patients
presenting with hematuria is much higher than that of 2.5%
PEG precipitates of sera from patients presenting no hematuria
at the time of testing. This is in agreement with the findings of
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Fig. 3. IgA immune complexes in 10 normal controls (A) and in 17
patients presenting with a Henoch—Schänlein purpura or an IgA
nephropathy (B). Results are expressed in ng/ml of sera. Horizontal
bars represent mean and SEM. IgA immune complexes in group B are
significantly higher than in group A (P < 0.01).
after before after
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Fig. 4. Effect of melibiose or of glucose incubation on the IgA content
of 2.5% PEG precipitates ofserafromfour normal controls (0) or from
8 patients presenting with either an IgA nephropathy or a Henoch—
Schönlein purpura (•). Results are expressed in ng/ml of sera.
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